Volume 14, Number 3—March 2008
Research
Epidemiology of Nontuberculous Mycobacteria in Patients without HIV Infection, New York City
Ethan E. Bodle*, Jennifer A. Cunningham*, Phyllis Della-Latta*, Neil W. Schluger*, and Lisa Saiman*
Table 3
Comparison of coexisting conditions and concomitant medications with body site of nontuberculous mycobacteria (NTM) disease, New York–Presbyterian Hospital, Columbia University Medical Center, New York, New York, 2000–2003
| Site of NTM disease | % Patients receiving concomitant medications (n = 79) |
||||
|---|---|---|---|---|---|
| Systemic steroids | Immunosuppressants | Chemotherapeutics | Immunomodulators | None | |
| Blood (n = 7) | 50 | 33 | 50 | 17 | 17 |
| Respiratory tract (n = 81) | 26 | 13 | 2 | 4 | 70 |
| Skin and soft tissue, surgical sites (n = 21) | 17 | 17 | 8 | 8 | 75 |
| All† | 25 | 15 | 6 | 5 | 66 |
*Defined as diabetes, chronic renal failure and/or rheumatologic disease.
†Includes 2 patients with disseminated disease following bone marrow transplantation, 1 patient with central nervous system disease receiving steroids, 1 patient with gastrointestinal disease, and 2 patients with lymph node disease/cancer.
Page created: July 07, 2010
Page updated: July 07, 2010
Page reviewed: July 07, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.